117 related articles for article (PubMed ID: 34086522)
1. Plasma circulating cell free messenger RNA as a potential biomarker of melanoma.
Ita MI; Wang JH; Fanning N; Kaar G; Lim C; Redmond HP
Acta Oncol; 2021 Sep; 60(9):1201-1209. PubMed ID: 34086522
[TBL] [Abstract][Full Text] [Related]
2. The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study.
Ita MI; Wang JH; Toulouse A; Lim C; Fanning N; O'Sullivan M; Nolan Y; Kaar GF; Redmond HP
Acta Neurochir (Wien); 2022 Mar; 164(3):723-735. PubMed ID: 34643804
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype.
Albrecht LJ; Höwner A; Griewank K; Lueong SS; von Neuhoff N; Horn PA; Sucker A; Paschen A; Livingstone E; Ugurel S; Zimmer L; Horn S; Siveke JT; Schadendorf D; Váraljai R; Roesch A
Clin Transl Med; 2022 Nov; 12(11):e1090. PubMed ID: 36320118
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Response Evaluation in Advanced Melanoma Patients Incorporating Plasma cfDNA, LDH, VEGF, PD-L1, and IFN-γ Measurements.
Ita MI; Wang JH; Heffron CC; Power DG; Nolan Y; Toulouse A; Lim CCH; Fanning N; Redmond HP
Anticancer Res; 2022 Feb; 42(2):801-810. PubMed ID: 35093878
[TBL] [Abstract][Full Text] [Related]
5. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
6. Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Mikoshiba A; Ashida A; Sakaizawa K; Kiniwa Y; Okuyama R
J Dermatol Sci; 2020 Mar; 97(3):172-178. PubMed ID: 31987696
[TBL] [Abstract][Full Text] [Related]
7. The potential of circulating cell free RNA as a biomarker in cancer.
Cheung KWE; Choi SR; Lee LTC; Lee NLE; Tsang HF; Cheng YT; Cho WCS; Wong EYL; Wong SCC
Expert Rev Mol Diagn; 2019 Jul; 19(7):579-590. PubMed ID: 31215265
[No Abstract] [Full Text] [Related]
8. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
9. Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.
Rutkowski P; Nowecki ZI; van Akkooi AC; Kulik J; Wanda M; Siedlecki JA; Eggermont AM; Ruka W
Ann Surg Oncol; 2010 Dec; 17(12):3314-23. PubMed ID: 20607422
[TBL] [Abstract][Full Text] [Related]
10. The predictive and prognostic significance of cell-free DNA concentration in melanoma.
Váraljai R; Elouali S; Lueong SS; Wistuba-Hamprecht K; Seremet T; Siveke JT; Becker JC; Sucker A; Paschen A; Horn PA; Neyns B; Weide B; Schadendorf D; Roesch A
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):387-395. PubMed ID: 32569440
[TBL] [Abstract][Full Text] [Related]
11. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
12. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
13. Prognostic molecular biomarkers for cutaneous malignant melanoma.
Tanaka R; Koyanagi K; Narita N; Kuo C; Hoon DS
J Surg Oncol; 2011 Sep; 104(4):438-46. PubMed ID: 21557225
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
15. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
16. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
Huang SK; Hoon DS
Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
Armand-Labit V; Meyer N; Casanova A; Bonnabau H; Platzer V; Tournier E; Sansas B; Verdun S; Thouvenot B; Hilselberger B; Doncescu A; Lamant L; Lacroix-Triki M; Favre G; Pradines A
Acta Derm Venereol; 2016 Jan; 96(1):29-34. PubMed ID: 26039581
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
